- 著者
- Kentaro Kobayashi Akio Kimura Ryo Sasaki Kayoko Hayakawa Norio Ohmagari Yasuo Sugiura Haruhito Sugiyama Norihiro Kokudo
- 出版者
- National Center for Global Health and Medicine
- 雑誌
- Global Health & Medicine (ISSN:24349186)
- 巻号頁・発行日
- vol.4, no.4, pp.230-232, 2022-08-31 (Released:2022-09-03)
- 参考文献数
- 3
- 被引用文献数
- 1
In preparation for the Tokyo 2020 Olympic and Paralympic Games, our hospital was responsible for accepting mainly media representatives, marketing partners, and other Games staff. Given that restricting our regular capacity to treat certain groups of patients could potentially result in social losses, to avoid this we made rigorous preparations for the entire hospital to accept Games-related patients. It was rational to set up a single 24-h contact point at the Emergency Department for making the decision on whether to accept the patient or not and for coordinating the patient's medical care. With respect to language support, International Health Care Center staffs were made available as interpreters on weekdays. Multilingual support was available all day via an application run on tablet devices. During a 67-day period, the hospital accepted 31 Games-related patients (mean age 43.4 years, male: female ratio 25:6). Eighteen patients were from Europe, 4 patients each were from North America and Asia, 2 each were from Central America, South America, and Africa, and 1 was from Oceania. The most common cause of visits was COVID-19, but none were severe cases. Other causes were diverse and included moderate and severe conditions. We summarized the challenges and experiences in handling Tokyo 2020 Games-related patients at a designated hospital during the COVID-19 pandemic
- 著者
- Norihiro Kokudo
- 出版者
- National Center for Global Health and Medicine
- 雑誌
- GHM Open (ISSN:2436293X)
- 巻号頁・発行日
- vol.1, no.1, pp.1-2, 2021-08-29 (Released:2021-09-01)
- 参考文献数
- 7
To generate high-quality evidence and serve as a platform for interdisciplinary communication regarding challenging issues in global health and medicine, we are launching a new open-access multispecialty journal — GHM Open (www.ghmopen.com) – with the goal of creating a network to share global health information and findings from basic science and clinical science for use in practice. GHM Open will be an inclusive and global journal; the diversity of our editorial board, authors, and reviewers will allow us to showcase rich and wide-ranging content, making it ever more relevant to researchers and clinicians around the world. The journal prioritizes specialized research with wider general relevance that will influence clinical care, global health, public health, medical education, and the direction of future research. We aim to be relevant, accessible, and enjoyable, not only to researchers but also to global health and medical care providers. We sincerely look forward to having you join us as a reader, author, reviewer, or editorial board member to address challenging issues in global health and medicine.
- 著者
- Tatsuo Sawakami Kenji Karako Peipei Song Wataru Sugiura Norihiro Kokudo
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- pp.2021.01269, (Released:2021-07-13)
- 参考文献数
- 26
- 被引用文献数
- 10
In Japan, the Law Concerning the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the "Infectious Diseases Control Law") classifies infectious diseases as category I-V infectious diseases, pandemic influenza, and designated infectious diseases based on their infectivity, severity, and impact on public health. COVID-19 was designated as a designated infectious disease as of February 1, 2020 and then classified under pandemic influenza as of February 13, 2021. According to national reports from sentinel surveillance, some infectious diseases transmitted by droplets, contact, or orally declined during the COVID-19 epidemic in Japan. As of week 22 (June 6, 2021), there were 704 cumulative cases of seasonal influenza, 8,144 cumulative cases of chickenpox, 356 cumulative cases of mycoplasma pneumonia, and 45 cumulative cases of rotavirus gastroenteritis; these numbers were significantly lower than those last year, with 563,487 cumulative cases of seasonal influenza, 31,785 cumulative cases of chickenpox, 3,518 cumulative cases of mycoplasma pneumonia, and 250 cumulative cases of rotavirus gastroenteritis. Similarly, many infectious diseases transmitted by droplets or contact declined in other countries and areas during the COVID-19 pandemic. One can reasonably assume that various measures adopted to control the transmission of COVID-19 have played a role in reducing the spread of other infectious diseases, and especially those transmitted by droplets or contact. Extensive and thorough implementation of personal protective measures and behavioral changes may serve as a valuable reference when identifying ways to reduce the spread of infectious diseases transmitted by droplets or contact in the future.
- 著者
- Norihiro Kokudo Haruhito Sugiyama
- 出版者
- National Center for Global Health and Medicine
- 雑誌
- Global Health & Medicine (ISSN:24349186)
- 巻号頁・発行日
- vol.3, no.2, pp.56-59, 2021-04-30 (Released:2021-05-08)
- 参考文献数
- 8
- 被引用文献数
- 29
The rapid global spread of the COVID-19 pandemic has posed a significant challenge to various countries in terms of the capacity of hospitals to admit and care for patients during the crisis. To estimate hospital capacity during the COVID-19 pandemic, clinicians working in tertiary hospitals around the world were surveyed regarding available COVID-19 hospital statistics. Data were obtained from 8 tertiary centers in 8 countries including the United States, United Kingdom, Switzerland, Turkey, Singapore, India, Pakistan, and Japan. The correlation between the number of patients with COVID-19 per 1 million population vs. the maximum number of inpatients with COVID-19 in a representative tertiary hospital in each country was determined, as was the correlation between COVID-19 deaths per 1 million population vs. the maximum number of patients with COVID-19 in the intensive care unit (ICU). What was noteworthy was that none of the 8 hospitals reduced emergency room (ER) activity even at the peak of the pandemic although treatment of patients without COVID-19 decreased by 0-70% depending on the extent of the epidemic. Although various measures are being actively implemented to slow the spread of the virus and reduce the strain on the health care system, the reality is that there are still a significant number of hospitals at risk of being overloaded in the event of a future surge in cases.
- 著者
- Kenji Karako Peipei Song Yu Chen Wei Tang Norihiro Kokudo
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- pp.2021.01019, (Released:2021-01-29)
- 参考文献数
- 40
- 被引用文献数
- 70
The first case of COVID-19 in Japan was reported on 16 January 2020. The total number of the infected has reached 313,844 and the number of deaths has reached 4,379 as of 16 January 2021. This article reviews the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-2021 in order to provide a reference for the next step in epidemic prevention and control. The Japanese Government declared a state of emergency on 7 April 2020, which suppressed the increase in the number of the infected by curtailing economic activity. The first wave peaked at 701 new cases a day and it decreased to 21 new cases on May 25 when the state of emergency was lifted. However, the number of the infected increased again due to the resumption of economic activity, with a peak of 1,762 new cases a day during the second wave. Although the situation was worse than that during the first wave, the government succeeded in limiting the increase without declaring a state of emergency again, and that may be attributed to a decrease in crowd activities and an increase in the number of inspections. During the third wave, the number of the infected continued to exceed the peak during previous waves for two months. Major factors for this rise include the government’s implementation of further policies to encourage certain activities, relaxed immigration restrictions, and people not reducing their level of activity. An even more serious problem is the bed usage for patients with COVID-19; bed usage exceeds 50% not only in major cities but also in various areas. On 7 January 2021, 5,953 new cases were reported a day; this greatly exceeded the previous peak, and the state of emergency was declared again. Although Japan has been preparing its medical system since the first wave, maintaining that system has imposed a large economic burden on medical facilities, hence stronger measures and additional support are urgently needed to combat COVID-19 in the coming few months.
- 著者
- Guohua Han Jufeng Xia Jianjun Gao Yoshinori Inagaki Wei Tang Norihiro Kokudo
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- Drug Discoveries & Therapeutics (ISSN:18817831)
- 巻号頁・発行日
- vol.9, no.1, pp.1-12, 2015-02-28 (Released:2015-03-18)
- 参考文献数
- 88
- 被引用文献数
- 29 78
Resveratrol (3, 5, 4'-trihydroxystilbene) is a phytoalexin contained in a variety of plants, such as grapes, berries and especially in the dried roots of Polygonum cuspidatum Sieb. et Zucc. It has been shown to exhibit anti-oxidative and anti-inflammation activity, and to reverse the effects of aging. Its ability to suppress cell proliferation, induce apoptosis and suppress the metastasis and invasion in a number of cell lines has prompted a large interest from people for its use as an anti-tumor component. In this review, evidence of resveratrol's anti-tumor effects and molecular mechanisms are recapitulated. First, we present the anti-apoptosis, anti-invasion/metastasis and anti-inflammation effect of resveratrol; second, the main signaling pathways involved in these activities are described and summarized with the studies of different tumors involved. Resveratrol not only induces apoptosis of tumor cells through intrinsic/extrinsic pathways and cell cycle arrest, but also inhibits the invasion and metastasis abilities of tumors via modulating collagen degradation-related molecular targets. Altogether, the present findings suggest the anti-tumor potential of resveratrol against various types of cancers.
- 著者
- Zhipeng Sun Wei Tang Yoshihiro Sakamoto Kiyoshi Hasegawa Norihiro Kokudo
- 出版者
- バイオ&ソーシャル・サイエンス推進国際研究交流会
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- vol.9, no.5, pp.284-288, 2015 (Released:2015-11-11)
- 参考文献数
- 15
- 被引用文献数
- 3 8
この論文は撤回されました。
- 著者
- Jufeng Xia Jianjun Gao Yoshinori Inagaki Norihiro Kokudo Munehiro Nakata Wei Tang
- 出版者
- バイオ&ソーシャル・サイエンス推進国際研究交流会
- 雑誌
- Drug Discoveries & Therapeutics (ISSN:18817831)
- 巻号頁・発行日
- vol.7, no.1, pp.1-8, 2013-02-28 (Released:2014-06-13)
- 参考文献数
- 75
- 被引用文献数
- 8 28
ABSTRACT: Numerous studies have documented that in cancer therapy flavonoids extracted from traditional Chinese medicine have anti-tumor activity or can enhance efficiency of chemotherapy in combination with chemotherapeutics. Thus, an awareness of flavonoids is needed by physicians and medical researchers. This review provides evidence about anti-hepatocellular carcinoma activity of flavonoids. First, as a common employed in vitro model, profile of HepG2 is shown. Second, the intracellular signaling pathways induced by flavonoids which inhibit the HepG2 cell line are summarized. Third, study situation of anti-HBV/HCV activity of flavonoids is shown. Our review is aimed at providing an understanding of anti-HBV/HCV activity and anti-HCC mechanisms of flavonoids, and an outlook on flavonoids application on cancer therapy.